Homeβ€ΊSearchβ€ΊLung Cancer: Targets and Therapy

Lung Cancer: Targets and Therapy

Dove Medical Press Ltd. Β· New Zealand Β· Est. 2010

ISSN1179-2728eISSN1179-2728
SJR Q2βœ“ WOS ESCIβœ“ Scopus / SJRβœ“ DOAJβœ“ Open Access
88
/ 100
High Trust
PubScope credibility score from verifiable indexing & ethics signals
Score Breakdown
β—† Scopus Q266
βœ“ Corroboration (4 more)+22
Total88
Level data: Norwegian Register (HK-dir), NLOD 2.0. Β· Third-party records Β· how this is calculated Β· Report an error β†’
⚑ Speed vs Prestige
How does this journal balance review speed with impact level?
16
weeks to publish Β· journal-reported
Average Β· vs ~15 wk median
Q2
SJR Rank
Top 50% in field
Impact Factor & Quartile Β· Web of Science (JCR)

βœ“ Indexed in the Web of Science Core Collection (ESCI) β€” Clarivate publishes an official Journal Impact Factor and JCR quartile for this journal.

See the official Impact Factor & quartile on the journal’s page β†—

The Impact Factor & JCR quartile are licensed by Clarivate β€” we link you to the official source instead of reprinting a number that can go out of date. Open metrics below: SCImago Q2. Source: Clarivate Journal Citation Reports.

SJR Scorei
1.028
H-Indexi
35
CiteScore
ViewΒ β†—
Scopus metric Β· on the journal’s page
SNIPi
0.809
Total Worksi
212
Total Citationsi
3,687
2yr Mean Citednessi
2.28
Open Impact Factor alternative

Aims & Scope

An international, peer-reviewed, open access journal focusing on lung cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

General Information

Country / RegionNew Zealand
Primary LanguageEnglish
1st Year Published2010
FrequencyIrregular
StatusActive (last: 2026)
Total Publications212
Publisher OrgDove Medical Press
OA Since2009
Visit Journal Website

Submission Info

Peer ReviewSingle-blind
Review Time~16 weeks
Acceptance Rateβ€”
OA LicenseCC BY, CC BY-NC
OA Rateβ€”

Ethics & Quality

COPE Memberβœ— No
OASPA Memberβœ— No
Not on Predatory Listsβœ“ Yes
Plagiarism Detectionβœ“ Yes

Think.Check.Submit Compliance

9/12 Β· 75%
βœ…
Do you know the journal / publisher?
Dove Medical Press Ltd.
βœ…
Does the journal have a website?
βœ“ Linked
βœ…
Is the ISSN verified?
1179-2728 / 1179-2728
βœ…
Indexed in a trusted database?
WoS, Scopus, DOAJ, PubMed
βœ…
Peer review process documented?
Single-blind
❌
Follows ethical publishing standards (COPE)?
N/A
❌
APC fees clearly disclosed?
N/A
βœ…
Not on predatory/blacklists?
βœ“ Clean
❌
Long-term digital preservation?
N/A
βœ…
Plagiarism detection in place?
Yes
βœ…
Listed in DOAJ (verified OA)?
DOAJ verified
βœ…
Primary language documented?
English

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published
Citations received
15
315
2019
13
168
2020
14
353
2021
8
96
2022
12
99
2023
19
86
2024
17
17
2025
7
1
2026

Source: OpenAlex Β· Each year’s green bar = citations earned by that year’s papers, counted to date β€” so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category β€” its quartile can differ by discipline.

OncologyQ2

Subject Classification

Web of Science Categories

Oncology

Scopus Categories

Oncology

Research Topics (OpenAlex)

Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and TreatmentColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsCancer therapeutics and mechanismsHER2/EGFR in Cancer ResearchCancer-related Molecular PathwaysNeuroendocrine Tumor Research Advances

Frequently asked questions about Lung Cancer: Targets and Therapy

Is Lung Cancer: Targets and Therapy a predatory journal?

PubScope has no integrity flags on record for Lung Cancer: Targets and Therapy: it is indexed in Web of Science, Scopus, DOAJ, and is not on DOAJ's withdrawn list. Its PubScope Trust Score is 88/100. Indexing is a transparency signal, not a guarantee β€” always confirm fit and policies before submitting.

What is the impact factor of Lung Cancer: Targets and Therapy?

Lung Cancer: Targets and Therapy is indexed in the Web of Science Core Collection, so Clarivate publishes an official Journal Impact Factor for it (since the 2023 Journal Citation Reports, every Core Collection journal β€” including Arts & Humanities and Emerging Sources titles β€” receives one). PubScope links to Clarivate's official source rather than reprinting the number, which can be out of date. Its open 2-year mean citedness is 2.28.

Is Lung Cancer: Targets and Therapy indexed in Scopus and Web of Science?

Lung Cancer: Targets and Therapy is indexed in Web of Science, Scopus, DOAJ.

What is the aims and scope of Lung Cancer: Targets and Therapy?

An international, peer-reviewed, open access journal focusing on lung cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

Compare This JournalFind Similar← Back to Search
Understand these signals
How to tell if a journal is predatoryWhat Q1–Q4 quartiles meanWeb of Science vs Scopus vs DOAJWhat is an APC?

Data updated: 2026-05-22 Β· Sources: SJR, DOAJ, OpenAlex, WoS, Crossref